Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 + Orelabrutinib in treatment-naïve CLL/SLL
NCT06378138Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- May 2024
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mesutoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by InnoCare Pharma. Started May 2024; status: recruiting.
02
Drugs
mesutoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06378138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378138.